During the secondary analysis, the considerably less conservative but clinically meaningful criterion of stable reaction (described like a fifty% or more reduction in MADRS from baseline for 2 months) was used. With the patients who attained secure response, 25.eight% in the esketamine group and 57.six% within the placebo group relapsed, https://conans503hig4.frewwebs.com/profile